Company profile for EnliTISA (Shanghai) Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

EnliTISA (Shanghai) Pharmaceutical Co., Ltd., a Chinese-Swedish biotech, develops treatments for inflammatory and fibrotic diseases with high unmet needs. It advances safer, more effective anti-inflammatory/anti-fibrosis drugs, with 16 patent applications (3 granted in China, US, others). Clinical milestones include completed Phase II for ARDS (China, Mar 2025), ongoing Phase Ib for radiation-induced oral mucositis (China), an...
EnliTISA (Shanghai) Pharmaceutical Co., Ltd., a Chinese-Swedish biotech, develops treatments for inflammatory and fibrotic diseases with high unmet needs. It advances safer, more effective anti-inflammatory/anti-fibrosis drugs, with 16 patent applications (3 granted in China, US, others). Clinical milestones include completed Phase II for ARDS (China, Mar 2025), ongoing Phase Ib for radiation-induced oral mucositis (China), and completed Phase I for IPF (Sweden, Dec 2024). Revenue-generating partnerships since 2021 include out-licensing with Shanghai Pharma; won silver in 2024 China Innovation Competition.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New Dist...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

SCOPE Summit

SCOPE Summit

Not Confirmed

envelop Contact Supplier

SCOPE Summit

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty